A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

NCT05555342 | Completed Early Phase 1 FDA Device

• 2 other identifiers: 1723UCI 21-222
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.

Conditions

Lung Tumor; Metastatic Cancer

Keywords

lung metastasis; Stereotactic Ablative Radiotherapy; Percutaneous ablation; irreversible electroporation

Outcome Measures

Primary Outcomes (1)

• Feasibility, measured as the number of patients completing both IRE and the single fraction of radiation

  Number of patients completing treatment of both IRE and the single fraction of radiation. Up to 6 replacements are allowed (total subjects 6-12)

  Up to 3 years

Secondary Outcomes (10)

• Number of grade 3-5 adverse events

  Up to 3 years

• Local failure at the treated site

  Up to 3 years

• Duration of response

  Up to 3 years

• Progression-free survival

  Up to 3 years

• Overall survival

  Up to 3 years

Study Arms (1)

IRE ablation and radiation therapy

EXPERIMENTAL

Patients will be treated with IRE ablation directed at the target lesion on day 1. Moderate-dose, single-fraction radiation therapy will be delivered to the target lesion on day 8 to day 15.

Procedure: Irreversible electroporation (IRE) ablation; Radiation: Radiation Therapy

Interventions

Irreversible electroporation (IRE) ablation PROCEDURE

IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.

IRE ablation and radiation therapy

Radiation Therapy RADIATION

Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.

IRE ablation and radiation therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically or cytologically confirmed metastatic cancer of any histology. There must be a lung tumor present, although the lung tumor does not specifically need to have been biopsied.
• Patients must have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.
• Patients may have received any number of prior systemic or local therapies. There will be no prespecified washout period prior to IRE. However, systemic therapy will be halted while receiving IRE and radiation, and can be restarted following completion of radiation therapy.
• Up to 3 lesions may be included for treatment. The selected lesion(s) should be amenable to ablation and irradiation and patients will be eligible for ablation and irradiation in the judgment of the treating radiologist and radiation oncologist. If more than one lesion is selected, they should be separated by at least 5 cm to minimize lung irradiation. The target lesion for treatment by IRE and radiation will be a tumor not previously treated by radiation. This target lesion must be measurable, defined as the ability to be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>10 mm with spiral CT scan. The upper limit to the target lesion is 6 cm maximal diameter, but it also must be planned to be encompassed entirely by an IRE ablative zone. Any number of IRE probes will be allowed such that the entire tumor can be ablated.
• Must be age ≥ 18 years. Children are excluded from this study but will be eligible for future pediatric trials, if applicable.
• \. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.
• Performance status: ECOG performance status ≤2 (Karnofsky ≥50%).
• Life expectancy of ≥3 months.
• Adequate organ and marrow function as defined below. Labs should be performed within 14 days of treatment.
• Platelets ≥50,000/mcL
• Hemoglobin ≥8 g/dL
• Absolute neutrophil count ≥1,000/mcL
• INR \<1.5
• Female patients of childbearing potential must have a negative urine or serum pregnancy during screening. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• The effects of ionizing radiation (i.e. radiation therapy) on the developing human fetus are known to have the potential for congenital abnormalities and fetal harm. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and until completion of radiation therapy. Should a woman become pregnant or suspect she is pregnant during this period, she should inform her treating physician immediately.

You may not qualify if:

• Patient's whose target lesion has been previously treated with radiation therapy.
• Patients who have not recovered from adverse events due to prior anti-cancer therapy administered.
• Patients may not be receiving any other investigational agents 2 weeks prior to enrollment and until end of all therapeutic interventions.
• Patients with cardiac arrhythmias, pacemakers, or implanted defibrillator.
• Patients with epilepsy.
• Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Patients must not be pregnant due to the potential for congenital abnormalities and fetal harm caused by ionizing radiation.
• Patients with disease amenable to curative intent therapy.
• Patient has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin.

Sponsors & Collaborators

• University of California, Irvine: lead

Study Sites (1)

Chao Family Comprehensive Cancer Center University of California, Irvine

Orange, California, 92868, United States

Location

Related Publications (1)

• Harris JP, Boyd C, Shi M, Reilly M, Simon A, Seyedin SN, Chen WP, Nagasaka M, Nabar R, Abi-Jaoudeh N. Pilot Study of Combining Stereotactic Body Radiation Therapy with Pulsed Field Ablation for Oligometastatic/Oligoprogressive Lung Tumors. J Vasc Interv Radiol. 2025 Nov;36(11):1687-1695. doi: 10.1016/j.jvir.2025.08.005. Epub 2025 Aug 11.

  PMID: 40803526 DERIVED

MeSH Terms

Conditions

Lung Neoplasms; Neoplasm Metastasis

Interventions

Electroporation; Radiotherapy

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cytological Techniques; Clinical Laboratory Techniques; Investigative Techniques; Electrochemical Techniques; Therapeutics

Study Officials

• Jeremy Harris, MD

  Chao Family Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Clinical Radiation Oncology

Study Record Dates

• First Submitted: September 20, 2022
• First Posted: September 26, 2022
• Study Start: January 3, 2023
• Primary Completion: September 29, 2023
• Study Completion: October 27, 2024
• Last Updated: May 14, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)